Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar 24;61(4):e02688-16.
doi: 10.1128/AAC.02688-16. Print 2017 Apr.

In Vitro Activity of Ceftolozane-Tazobactam against Multidrug-Resistant Nonfermenting Gram-Negative Bacilli Isolated from Patients with Cystic Fibrosis

Patrick Grohs  1 , Gary Taieb  1 , Philippe Morand  2   3 , Iheb Kaibi  1 , Isabelle Podglajen  1   3 , Marie Lavollay  1   3   4 , Jean-Luc Mainardi  1   3   4 , Fabrice Compain  5   3   4
Affiliations

In Vitro Activity of Ceftolozane-Tazobactam against Multidrug-Resistant Nonfermenting Gram-Negative Bacilli Isolated from Patients with Cystic Fibrosis

Patrick Grohs et al. Antimicrob Agents Chemother. .

Abstract

Ceftolozane-tazobactam was tested against 58 multidrug-resistant nonfermenting Gram-negative bacilli (35 Pseudomonas aeruginosa, 11 Achromobacter xylosoxydans, and 12 Stenotrophomonas maltophilia isolates) isolated from cystic fibrosis patients and was compared to ceftolozane alone, ceftazidime, meropenem, and piperacillin-tazobactam. Ceftolozane-tazobactam was the most active agent against P. aeruginosa but was inactive against A. xylosoxydans and S. maltophilia In time-kill experiments, ceftolozane-tazobactam had complete bactericidal activity against 2/6 clinical isolates (33%).

Keywords: Achromobacter; Pseudomonas; Stenotrophomonas; bactericidal activity; ceftolozane; cystic fibrosis.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Time-kill curves for P. aeruginosa ATCC 27853 exposed to antimicrobial agents at 4× MIC (A) or 8× MIC (B). Antibiotics were added to the medium after 2 h of incubation. □, growth control; ▲, ceftolozane alone; △, ceftolozane-tazobactam; ●, ceftazidime; ■, piperacillin-tazobactam; ◆, meropenem.
FIG 2
FIG 2
Time-kill curves for clinical P. aeruginosa isolates exposed to ceftolozane-tazobactam. Antibiotics were added to the medium after 2 h of incubation. The MICs, for three isolates each, were 4 μg/ml (A to C) or 8 μg/ml (D to F). □, growth control; ▲, 4× MIC; ●, 8× MIC.
See this image and copyright information in PMC

References

    1. Burns JL, Emerson J, Stapp JR, Yim DL, Krzewinski J, Louden L, Ramsey BW, Clausen CR. 1998. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis 27:158–163. doi: 10.1086/514631. - DOI - PubMed
    1. Lyczak JB, Cannon CL, Pier GB. 2002. Lung infections associated with cystic fibrosis. Clin Microbiol Rev 15:194–222. doi: 10.1128/CMR.15.2.194-222.2002. - DOI - PMC - PubMed
    1. Flume PA, Mogayzel PJ, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, Marshall BC. 2009. Cystic fibrosis pulmonary guidelines. Am J Respir Crit Care Med 180:802–808. doi: 10.1164/rccm.200812-1845PP. - DOI - PubMed
    1. Waters V, Atenafu EG, Lu A, Yau Y, Tullis E, Ratjen F. 2013. Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients. J Cyst Fibros 12:482–486. doi: 10.1016/j.jcf.2012.12.006. - DOI - PubMed
    1. De Baets F, Schelstraete P, Van Daele S, Haerynck F, Vaneechoutte M. 2007. Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance. J Cyst Fibros 6:75–78. doi: 10.1016/j.jcf.2006.05.011. - DOI - PubMed

MeSH terms